• Mashup Score: 0

    The FDA has approved Pfizer’s 2 mg once-daily Velsipity, an oral, selective sphingosine-1-phosphate receptor modulator, to treat adult patients with moderately to severely active ulcerative colitis, according to a company press release. This approval designates Velsipity (etrasimod) as only the second S1P receptor modulator available for the treatment of UC since Zeposia (Ozanimod, Bristol

    Tweet Tweets with this article
    • #ICYMI from @US_FDA, @pfizer: #FDA approves #Pfizer’s #Velsipity 💊 as ‘oral, once-daily pill’ for #ulcerativecolitis https://t.co/YWtJom5soo

  • Mashup Score: 0

    Although both are safe and effective, the Moderna COVID-19 vaccine was linked to greater protection and a slightly lower risk for adverse events compared with the Pfizer-BioNTech vaccine in older adults, data in JAMA Network Open show. Daniel A. Harris, PhD, a research scientist at Brown University School of Public Health, and colleagues wrote that head-to-head comparisons of the messenger

    Tweet Tweets with this article
    • 💉 The #Moderna #COVID19 vaccines had lower risk of adverse events versus #Pfizer's #vaccine and was linked to greater protection against #infection. #healthnews #MedTwitter https://t.co/WdhBcD8I21

  • Mashup Score: 6

    If endorsed by CDC director Rochelle Walensky, the recommendation may lead to lower uptake than vaccine makers had hoped.

    Tweet Tweets with this article
    • #ACIP foregoes a stronger "should" recommendation, votes that adults 60 & older "may" get an #RSV vaccine if they & their health-care provider deem it of value to them. This would not have been the recommendation #GSK & #Pfizer were hoping for. https://t.co/XsZJt57MVq